Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.

Yaxiong ZhangZihong ChenYu LiuLiang HanWei JiangQiming WangJianhua ShiLiqin LuJianying LiMingjun ZhangYan HuangYunpeng YangXue Hou Li Zhang Jing LiWenfeng FangGang Chen

Published in: Cancer medicine (2024)

Combination of chidamide and envafolimab showed efficacy signals in certain NSCLC patients. But further identification of beneficial population is necessary for precision treatment.

Keyphrases

open label
end stage renal disease
small cell lung cancer
newly diagnosed
clinical trial
ejection fraction
single cell
prognostic factors
squamous cell carcinoma
study protocol
peritoneal dialysis
brain metastases